Recent FDA decisions added new options for dermatologists involved in treating patients with psoriasis, bullous pemphigoid ...

Ustekinumab is one of the first 10 medicines that are subject to negotiations. Medicare will select as many as 15 additional drugs covered under Part D for negotiation in 2025, ...

Pyzchiva (ustekinumab-ttwe; Sandoz), Selarsdi (ustekinumab-aekn; Teva and Alvotech), and Yesintek (ustekinumab-kfce; Biocon Biologics), all biosimilars to Stelara (ustekinumab; Johnson & Johnson ...

Otulfi (ustekinumab-aauz) is an IL-12/23 antagonist indicated for treatment of adult patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy; ...

Ustekinumab binds to two cytokines, IL-12 and IL-23, that are involved in inflammatory and immune responses.2 The biosimilar has been launched in Canada as JAMTEKI™, in Europe as UZPRUVO® and ...

OTULFI (ustekinumab-aauz) is contraindicated in patients with clinically significant hypersensitivity to ustekinumab products or to any of the excipients in OTULFI (ustekinumab-aauz). Infections ...

Ustekinumab is a human monoclonal antibody that targets the p40 protein, which is shared by interleukin (IL)-12 and IL-23 cytokines, known to be significant in the treatment of immune-mediated and ...

Celltrion today announced the U.S. launch of STEQEYMA® (ustekinumab-stba), a biosimilar to STELARA® (ustekinumab), following approval by the U.S. Food and Drug Administration (FDA) in December 2024.

Study: Risankizumab versus Ustekinumab for Moderate-to-Severe Crohn’s Disease. Image Credit: vitstudio / Shutterstock.com. Current treatment options for Crohn’s disease. Crohn’s disease is a ...

In treatment period 1, study participants (N=509) were randomly assigned 1:1 to receive either ustekinumab-stba or Stelara 45mg (baseline ≤100 kg) or 90mg (baseline >100kg) subcutaneously from ...

Ustekinumab products may decrease the protective effect of allergen immunotherapy (decrease tolerance) which may increase the risk of an allergic reaction to a dose of allergen immunotherapy.

Ustekinumab binds to two cytokines, IL-12 and IL-23, that are involved in inflammatory and immune responses. 2 The biosimilar has been launched in Canada as JAMTEKI™, in Europe as UZPRUVO ® and ...